Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec 8;5(1):e1115641.
doi: 10.1080/2162402X.2015.1115641. eCollection 2016.

First oncolytic virus approved for melanoma immunotherapy

Jonathan Pol  1 , Guido Kroemer  2 , Lorenzo Galluzzi  3
Affiliations

First oncolytic virus approved for melanoma immunotherapy

Jonathan Pol et al. Oncoimmunology. .

Abstract

On 2015, October 27th, the US Food and Drug Administration (FDA) has officially approved talimogene laherparepvec (T-VEC, also known as OncoVEXGM-CSF) for use in melanoma patients with injectable but non-resectable lesions in the skin and lymph nodes. T-VEC (which is commercialized by Amgen, Inc. under the name of Imlygic®) becomes therefore the first oncolytic virus approved for cancer therapy in the US.

Keywords: Granulocyte macrophage colony-stimulating factor; Imlygic®; OPTiM; OncoVEXGM-CSF; T-vec; talimogene laherparepvec.

PubMed Disclaimer

References

    1. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30:658–70; PMID:22781695; http://dx.doi.org/10.1038/nbt.2287 - DOI - PMC - PubMed
    1. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 2015; 14:642–62; PMID:26323545; http://dx.doi.org/10.1038/nrd4663 - DOI - PMC - PubMed
    1. Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, Erbs P, Limacher JM, Preville X, Zitvogel L et al. . Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology 2014; 3:e28694; PMID:25097804; http://dx.doi.org/10.4161/onci.28694 - DOI - PMC - PubMed
    1. Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology 2013; 2:e24612; PMID:23894720; http://dx.doi.org/10.4161/onci.24612 - DOI - PMC - PubMed
    1. Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, McGrath Y, Thomas SK, Thornton M, Bullock P et al. . ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003; 10:292–303; PMID:12595888; http://dx.doi.org/10.1038/sj.gt.3301885 - DOI - PubMed

Publication types

LinkOut - more resources